CAMBRIDGE, England & BOSTON --(BUSINESS WIRE)--Aug. 11, 2020-- Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide ( Bicycle ® ) technology, today announced the appointment of Dominic

CAMBRIDGE, England & BOSTON --(BUSINESS WIRE)--Aug. 5, 2020-- Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide ( Bicycle ®) technology, today announced that management will

- Progress across pipeline continues with BT1718 Phase IIa and BT8009 Phase I/II trial initiations on-track for this year - Cash was $96.9 million at June 30, 2020 , which excludes $17.6 million net proceeds from ATM offering program and a $6.7 million   UK R&D tax credit, both received in July

CAMBRIDGE, England & BOSTON --(BUSINESS WIRE)--Jun. 23, 2020-- Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide ( Bicycle ®) technology, today announced the appointment of Sir Keith

CAMBRIDGE, England & BOSTON --(BUSINESS WIRE)--Jun. 22, 2020-- Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide ( Bicycle ® ) technology, today announced that new translational data

CAMBRIDGE, England & BOSTON --(BUSINESS WIRE)--May 27, 2020-- Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide ( Bicycle ®) technology, today announced that management will

CAMBRIDGE, England & BOSTON --(BUSINESS WIRE)--May 15, 2020-- Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced that new translational research

CAMBRIDGE, England & BOSTON --(BUSINESS WIRE)--May 13, 2020-- Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide ( Bicycle ®) technology, today announced that a poster describing the

- BT5528 optimized to have distinct physiochemical and in vivo properties thought to enable more favorable preclinical safety, efficacy profiles than those of an antibody drug conjugate CAMBRIDGE, England & BOSTON --(BUSINESS WIRE)--May 12, 2020-- Bicycle Therapeutics plc (NASDAQ: BCYC), a

- Significant recent progress achieved across pipeline of innovative Bicycle ® - based therapies for oncology and beyond - Dosing underway in Phase I dose escalation of BT5528 in combination with nivolumab - Continued to strengthen corporate leadership with appointment of General Counsel - Cash was